Several potential disease-modifying drugs for Alzheimer's disease (AD) have failed to show
any effect on disease progression in clinical trials, conceivably because the AD subjects are …

Background The cerebrospinal fluid (CSF) biomarkers amyloid beta 1–42, total tau, and
phosphorylated tau are used increasingly for Alzheimer's disease (AD) research and patient …

Objective Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD)
in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects. Methods Amyloid‐β 1 to …

Background A growing body of evidence suggests that the plasma concentration of the
neurofilament light chain (NfL) might be considered a plasma biomarker for the screening of …

In this report, we present the results of a multicenter study to test analytic and diagnostic
performance of soluble forms of amyloid precursor proteins α and β (sAPPα and sAPPβ) in the …

Erythropoietin (EPO) promotes neuronal survival after hypoxia and other metabolic insults
by largely unknown mechanisms. Apoptosis and necrosis have been proposed as …

Background Erythropoietin (EPO) and its receptor play a major role in embryonic brain, are
weakly expressed in normal postnatal/adult brain and up-regulated upon metabolic stress. …

Biochemical markers have a central position in the diagnosis and management of patients
in clinical medicine, and also in clinical research and drug development, also for brain …

Background The cerebrospinal fluid (CSF) biomarkers amyloid β (Aβ)‐42, total‐tau (T‐tau),
and phosphorylated‐tau (P‐tau) demonstrate good diagnostic accuracy for Alzheimer's …

The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ 42 ), total
Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau 181 ) have proven diagnostic …